ClinicalTrials.gg
CompletedNCT02966834Updated May 4, 2021Results posted

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

A Phase 2 interventional study of Placebo and GSK2330672 in Cholestasis, sponsored by GlaxoSmithKline. Completed at 66 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-05-04.

Primary conditionLiver Cirrhosis, BiliaryRegistry: CholestasisReclassifiedWhy we changed it
Registry
Cholestasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Liver Cirrhosis, Biliary
Why
  1. The study's title name Liver Cirrhosis, Biliary, a narrower term within Cholestasis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is being conducted to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). Participants will receive either placebo or one of the 4 dose regimens of GSK2330672 (20 milligram [mg], 90 mg or 180 mg taken once daily or 90 mg twice daily). Participants on GSK2330672 will also receive placebo tablets to maintain blinding. The study has a prospectively defined adaptive design that will utilize interim data to further inform and potentially optimize the doses under investigation. Hence, additional dose regimen may be added during study. The total duration of a participant in the study will be up to 45 days of screening and 24 weeks of study including follow-up.

02

Conditions studied

  • Cholestasis

Browse trials for

Keywords

  • linerixibat
  • PBC
  • itch
  • GSK2330672
  • GLIMMER
  • primary biliary cholangitis
  • pruritus
03

In context

Liver Cirrhosis, Biliary Reclassified

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

This study's enrollment of 147 is above the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.

Browse Liver Cirrhosis, Biliary studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Liver Cirrhosis, Biliary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cholestasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 80 years of age inclusive, at the time of signing the .
  • Participants who have proven PBC, as demonstrated by having at least 2 of the following: History of sustained increased ALP levels > first recognized at least 6 months prior to the Screening Visit (Sustained ALP elevations at the time of Screening is not required, recognizing that the ALP may have decreased after institution of ursodeoxycholic acid (UDCA) therapy as described in inclusion number 4). Documented positive anti-mitochondrial antibody (AMA) titer (>1:40 titer on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay) or PBC-specific antinuclear antibodies (antinuclear dot and/or nuclear rim positive). Liver (at any time in the past) consistent with PBC.
  • Participants must rate their itch severity as being >=4 on a 0 to 10 point scale for the majority of time (at least half the days, as recalled by the participant) during the 8 weeks prior to the Screening Visit. Periods of low itch or no itch are acceptable as long as the worst daily itch score is >=4 on the majority of days.
  • Participants who are currently taking UDCA should be on stable doses of UDCA for >8 weeks at time of screening. Participants not taking UDCA due to intolerance may be enrolled 8 weeks after their last dose of UDCA. No changes or discontinuation is permitted until completion of the Main Study Period.
  • Male and/or female: Female participants- A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of (WOCBP) or a WOCBP who agrees to follow the guidance during the treatment period and until at least 4 weeks after the last dose of study treatment.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria

  • Screening total >2x . Total bilirubin >2x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent (%).
  • Screening or AST >6x ULN.
  • Screening \<45 milliliter (mL)/minute/1.73 square meter (m\^2) based on the CKD-EPI.
  • History or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy or ascites).
  • Presence of actively replicating viral hepatitis due to or C virus (HBV, ) infection, and/or confirmed hepatocellular carcinoma or biliary cancer. Other hepatic conditions ( e.g., primary sclerosing cholangitis [PSC], alcoholic liver disease, hepatitis, non-alcoholic steatohepatitis [NASH] ) are permitted if PBC is the dominant liver injury in the investigator's opinion.
  • Current diarrhea.
  • Current symptomatic cholelithiasis or inflammatory gall bladder disease. Participants with history of cholecystectomy >=3 months before screening may be eligible for enrolment.
  • Any current medical condition (e.g. psychiatric disorder, senility or dementia), which may affect the participant's ability to comply with the protocol specified procedures.
  • Initiation or increase in dose of colchicine, methotrexate, azathioprine, or systemic in the 2 months prior to screening. If a change in dose in any of these medications is anticipated during the course of the study, the participant should be excluded.
  • Initiation or increase in dose of bezafibrate or fenofibrate at any time during the 3 months prior to screening. Participants may join the study on stable doses of these medications, but no change or discontinuation is permitted until completion of the Main Study Period.
  • Initiation or increase in dose of any of the following in the 8 weeks prior to screening: rifampicin, naltrexone, naloxone, nalfurafine, or sertraline. Participants may join the study on stable or decreased doses of these medications, but no change in dose is permitted until completion of the Main Study Period.
  • Bile acid binding resin use: a participant must discontinue use of cholestyramine, colesevelam, colestipol or colestimide prior to the start of the Initial Study Period (no later than Day-2). Note: these drugs may be administered after completion of the Main Study Period, if clinically indicated.
  • Obeticholic acid use: a participant must discontinue use of obeticholic acid at least 8 weeks prior to the start of the Initial Study Period and may not restart until after the end of the study.
  • Administration of any other Inhibitor of the Human Ileal Bile Acid Transporter (IBAT) in the 3 months prior to screening.
  • Current enrolment or participation within the 8 weeks before start of the Initial Study Period, in any other clinical study involving an study treatment.
  • corrected for heart rate QTc >480 millisecond (msec).
  • History of sensitivity to the study treatment or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation in the study.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 gram of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 measure (25 mL) of spirits.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
147 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive matching placebo

    Drug: Placebo

  • Experimental
    GSK2330672 20 mg once daily

    Participants will receive GSK2330672 and matching placebo to maintain blind

    Drug: Placebo · Drug: GSK2330672

  • Experimental
    GSK2330672 90 mg once daily

    Participants will receive GSK2330672 and matching placebo to maintain blind

    Drug: Placebo · Drug: GSK2330672

  • Experimental
    GSK2330672 180 mg once daily

    Participants will receive GSK2330672 and matching placebo to maintain blind

    Drug: Placebo · Drug: GSK2330672

  • Experimental
    GSK2330672 40 mg twice daily

    Participants will receive GSK2330672 and matching placebo to maintain blind

    Drug: Placebo · Drug: GSK2330672

  • Experimental
    GSK2330672 90 mg twice daily

    Participants will receive GSK2330672 and matching placebo to maintain blind

    Drug: Placebo · Drug: GSK2330672

Interventions

  • DrugPlacebo

    GSK2330672 matching placebo will be supplied as white film-coated tablets.

  • GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline at Week 16 in the Mean Worst Daily Itch Score

    Participants were required to score the severity of their itching using a 0-10 numerical rating scale (NRS) where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Baseline is the average of the scores in the 7 days prior to the Week 4 (Visit 3 \[V3\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was done using Analysis of covariance (ANCOVA) including treatment group and centered Mean Worst Daily Itch score at Baseline.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Mean Change From Baseline at Week 16 in Primary Biliary Cholangitis-40 (PBC-40) Scale

    PBC-40 is a disease-specific health-related quality of life (HRQoL) questionnaire for use in PBC participants. It consists of 40 questions arranged in 6 domains with 3 to 11 questions in each domain. Each question is scored from 1 (least impact) to 5 (greatest impact). All questions within a domain are summed to obtain individual domain score. Domains were: Symptoms (7 questions) with score range 7-35, Itch (3 questions) with score range 3-15, Fatigue (11 questions) with score range 11-55, Cognitive (6 questions) with score range 6-30, Emotional (3 questions) with score range 3-15, and Social (10 questions) with score range 10-50. Higher scores for individual domains represent a poor quality of life. Baseline is the assessment performed at Week 4 (V3) which is conducted prior to first dosing of randomized medication that evening. Change from Baseline was calculated as post-Baseline value minus Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.

    Time frame: Baseline and at Week 16

  2. Mean Change From Baseline at Week 16 in Serum Alkaline Phosphatase (ALP) Concentrations, in Participants With High Risk of PBC Progression

    Criteria for high risk of PBC progression is defined as serum ALP concentrations more than or equal to (\>=)1.67 times upper limit of normal (ULN) range and/or total bilirubin concentrations more than (\>)ULN at Day 1. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 (Day 1) or Visit 1 (Screening), excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.

    Time frame: Baseline and at Week 16

  3. Number of Participants With Serum ALP Concentrations Less Than (<)1.67 Times ULN and Total Bilirubin Concentrations Less Than or Equal to (<=) ULN at Week 16

    Number of participants with ALP \< 1.67 times ULN and total bilirubin \<= ULN at Week 16 is presented. The endpoint was analyzed in Restricted High Risk Population.

    Time frame: At Week 16

  4. Mean Change From Baseline at Week 16 in Serum Alanine Aminotransferase (ALT) Among Those With a High Risk of PBC Progression

    Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including Treatment group and Baseline.

    Time frame: Baseline and at Week 16

  5. Mean Change From Baseline at Week 16 in Serum Aspartate Aminotransferase (AST) Among Those With a High Risk of PBC Progression

    Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including Treatment group and Baseline.

    Time frame: Baseline and at Week 16

  6. Mean Change From Baseline at Week 16 in Serum Gamma Glutamyl Transferase (GGT), Among Those With a High Risk of PBC Progression

    Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.

    Time frame: Baseline and at Week 16

  7. Mean Change From Baseline at Week 16 in Total Bilirubin Concentration, Among Those With a High Risk of PBC Progression

    Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.

    Time frame: Baseline and at Week 16

  8. Mean Change From Baseline at Week 16 in Albumin Concentration, Among Those With a High Risk of PBC Progression

    Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.

    Time frame: Baseline and at Week 16

  9. Mean Change From Baseline at Week 16 in Prothrombin International Normalized Ratio (INR), Among Those With a High Risk of PBC Progression

    Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.

    Time frame: Baseline and at Week 16

  10. Mean Change From Baseline at Week 16 in Prothrombin Time, Among Those With a High Risk of PBC Progression

    Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.

    Time frame: Baseline and at Week 16

  11. Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) -Main Study Period

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.

    Time frame: Up to 12 weeks

  12. Number of Participants With Non-SAEs and SAEs -Final Study Period

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.

    Time frame: Up to 4 weeks

  13. Number of Participants With Non-SAEs and SAEs - Follow-up Period

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.

    Time frame: Up to 4 weeks

  14. Number of Participants With Clinical Chemistry Data of Potential Clinical Importance

    Blood samples were collected to measure analyze the following parameters: albumin, calcium, Glomerular filtration rate (GFR) from creatinine, glucose, potassium and sodium. Participants were counted in the worst case category that their value changes to (low, within range \[w/in\] or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (for example \[e.g.\], high to high), or whose value became within range, were recorded in the "To w/in Range or No Change" category. Participants were counted twice if the participant had values that changed "To Low" and "To High", so the percentages may not add to 100 percent (%). Only "To Low" and/or "To High" categories with potential clinical importance data have been presented.

    Time frame: At Weeks 8, 12, 16 and 20

  15. Number of Participants With Hematology Data of Potential Clinical Importance

    Blood samples were collected to analyze the following parameters: hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. Participants were counted in the worst case category that their value changes to (low, w/in or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., high to high), or whose value became within range, were recorded in the "To w/in Range or No Change" category. Participants were counted twice if the participant had values that changed "To Low" and "To High", so the percentages may not add to 100%. Only "To Low" and/or "To High" categories with potential clinical importance data have been presented.

    Time frame: At Weeks 8, 12, 16 and 20

  16. Number of Participants With Abnormal 12-Lead Electrocardiogram (ECG) Parameters

    A 12-lead ECG was recorded with the participant in a semi-supine position. 12-lead ECGs were obtained by using an automated ECG machine. Data for abnormal, not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

    Time frame: At Weeks 8, 12, 16 and 20

  17. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 20

  18. Change From Baseline in Pulse Rate

    Pulse rate was measured in a semi-supine position after 5 minutes of rest. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and Week 20

  19. Change From Baseline in Gastrointestinal Symptom Rating Scale (GSRS) Assessment

    GSRS is a validated scale used to assess gastrointestinal symptoms experienced by participants over the preceding 5 to 7 days. GSRS was measured for all 5 domains: Average Diarrhea Syndrome Score, Average Indigestion Syndrome Score, Average Constipation Syndrome Score, Average Abdominal Pain Syndrome Score, Average Reflux Syndrome Score. All individual domains are scored on a 7-point Likert scale ranging from 1(not at all) to 7(extremely). Higher score indicate more severe symptoms. The Average Total GSRS score was mean of these 5 domains and ranges from 1 to 7. Higher score indicates worst possible degree of symptoms. The responses summarized at each visit are those given during the week prior to the visit, with exception of Day 1. Baseline is the most recent assessment completed by participant prior to randomization. Change from Baseline was calculated as post-Baseline value minus the Baseline value. Data has been presented for each domain along with the average Total GSRS score.

    Time frame: Baseline and Week 20

  20. Number of Participants With Mean Worst Daily Itch Score of <4 at Week 16

    Participants were required to score the severity of their itching using a 0-10 NRS where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Number of participants with Mean Worst Daily Itch Score of \<4 at Week 16 is presented.

    Time frame: At Week 16

  21. Number of Participants With Improvement of >= 30 Percent (%) in the Mean Worst Daily Itch Score at Week 16 From Baseline

    Participants were required to score the severity of their itching using a 0-10 NRS where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Baseline is the most recent assessment completed by the participant prior to randomization. Number of participants with improvement of \>= 30% in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented.

    Time frame: Baseline and At Week 16

  22. Number of Participants With Improvement of >=2 in the Mean Worst Daily Itch Score at Week 16 From Baseline

    Participants were required to score the severity of their itching using a 0-10 NRS where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Baseline is the most recent assessment completed by the participant prior to randomization. Number of participants with improvement of \>=2 in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented.

    Time frame: Baseline and At Week 16

  23. Percentage of Responder Days With Worst Daily Itch Score of <4

    Percentage of Responder Days with Worst Daily Itch score was calculated as: (number of days response from Visit 3+1 to Visit 6-1 divided by number of days from Visit 3+1 to Visit 6-1 with worst daily itch scores available) times 100. Days for which no worst daily itch score was available did not contribute to either the numerator or the denominator. Analysis was performed using ANCOVA model including treatment group. Percentage of responder days with Worst Daily Itch Score of \<4 is presented.

    Time frame: Up to Week 16

  24. Percentage of Responder Days With Improvement of >= 30% in the Mean Worst Daily Itch Score at Week 16 From Baseline

    Percentage of Responder Days with Worst Daily Itch score was calculated as: (number of days response from Visit 3+1 to Visit 6-1 divided by number of days from Visit 3+1 to Visit 6-1 with worst daily itch scores available) times 100. Days for which no worst daily itch score was available did not contribute to either the numerator or the denominator. Analysis was performed using ANCOVA model including treatment group. Baseline is the most recent assessment completed by the participant prior to randomization. Percentage of responder days with improvement of \>= 30% in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented..

    Time frame: Baseline and at Week 16

  25. Percentage of Responder Days With Improvement of >=2 in the Mean Worst Daily Itch Score at Week 16 From Baseline

    Percentage of Responder Days with Worst Daily Itch was calculated as: (number of days response from Visit 3+1 to Visit 6-1 divided by number of days from Visit 3+1 to Visit 6-1 with worst daily itch scores available) times 100. Days for which no worst daily itch score was available did not contribute to either the numerator or the denominator. Analysis was performed using ANCOVA model including treatment group. Baseline is the most recent assessment completed by the participant prior to randomization. Percentage of responder days with improvement of \>=2 in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented.

    Time frame: Baseline and at Week 16

  26. Change From Baseline in the Mean Daily Sleep Score at Week 16

    Mean Daily Sleep Score is defined as the average of the daily sleep scores provided in the 7 days prior to the relevant visit. Participants sleep quality was recorded in an electronic diary each morning using a 0-10 NRS in which 0: good sleep to 10:worst possible sleep. Higher score indicates worse possible sleep. Baseline is the average of the scores in the 7 days prior to the Week 4 (V3) visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.

    Time frame: Baseline and at Week 16

  27. Change From Baseline in the Mean Daily Fatigue Score at Week 16

    Mean Daily Fatigue Score is defined as the average of the daily fatigue scores provided in the 7 days prior to the relevant visit. Participants fatigue level was recorded in an electronic diary each evening using a 0-10 NRS in which 0: no fatigue to 10:worst possible fatigue. Higher score indicates worse possible fatigue. Baseline is the average of the scores in the 7 days prior to the Week 4 (V3) visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.

    Time frame: Baseline and at Week 16

  28. Change From Baseline in the Five-Dimensional (5-D) Itch Scale at Week 16

    The 5-D itch scale had been developed as a brief, single page, instrument for the multidimensional quantification of itch that is sensitive to change over time. It has data to support its validity in a population of participants with pruritus and covers five dimensions of itch experienced by participants: duration, degree, direction, disability and distribution. Each domain was scored on a 5-point scale, ranging from 1 (Not present/resolved/never) to 5 (unbearable/getting worse/always), higher scores indicates worst itching. The scores of each of five domains were achieved separately and then summed together to obtain a total 5-D score. A total 5-D scores potentially ranged between 5 (no pruritus) and 25 (most severe pruritus) where higher score indicates worse possible itching. Baseline is assessment performed at Week 4 (V3) which is conducted prior to first dosing of randomized medication that evening. Change from Baseline was calculated as post-Baseline value minus Baseline value.

    Time frame: Baseline and at Week 16

  29. Mean Change From Baseline at Week 16 in Serum Total Bile Acid Concentration

    Blood samples were collected for evaluating total bile acid concentration as a biomarker of PBC. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and at Week 16

  30. Mean Change From Baseline at Week 16 in Serum 7-alpha Hydroxy-4-cholesten-3-one (C4)

    Blood samples were collected for evaluating C4 concentration as a marker of bile acid synthesis. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline and at Week 16

  31. Plasma Concentration of GSK2330672 After Sparse Sampling

    Blood samples were collected for measurement of plasma GSK2330672 concentration.

    Time frame: At Week 4 (between 1 and 3 hours post-dose) and At Weeks 8, 12 and 16 (between 1 and 3 hours post-dose, and between 5 and 8 hours post-dose)

07

Results

Posted May 4, 2021

Participant flow

This study was conducted across 66 centers in 10 countries. The 40 milligrams (mg) twice daily dose group was added and recruitment into the 20 mg twice daily dose group was discontinued following the pre-specified interim analysis.

Main Study Period (Up to 12 Weeks)
Participant flow — Main Study Period (Up to 12 Weeks)
MilestonePlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Started361623272322
Completed351619192217
Not completed104815
Withdrew: Adverse event000010
Withdrew: Lack of efficacy100000
Withdrew: Discontinued study treatment and entered follow-up004805
Final Study Period (Up to 4 Weeks)
Participant flow — Final Study Period (Up to 4 Weeks)
MilestonePlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Started351619192117
Completed351619192117
Not completed000000
Follow-up (Up to 4 Weeks)
Participant flow — Follow-up (Up to 4 Weeks)
MilestonePlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Started351623272222
Completed351622222221
Not completed001501
Withdrew: Adverse event001201
Withdrew: Withdrawal by subject000200
Withdrew: Protocol violation000100

Outcome measures

PrimaryMean Change From Baseline at Week 16 in the Mean Worst Daily Itch Score

Participants were required to score the severity of their itching using a 0-10 numerical rating scale (NRS) where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Baseline is the average of the scores in the 7 days prior to the Week 4 (Visit 3 \[V3\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was done using Analysis of covariance (ANCOVA) including treatment group and centered Mean Worst Daily Itch score at Baseline.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline at Week 16 in the Mean Worst Daily Itch Score
Scores on a scalePlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Mean Change From Baseline at Week 16 in the Mean Worst Daily Itch Score-1.73 (-2.44 to -1.01)-2.19 (-3.26 to -1.12)-2.60 (-3.55 to -1.65)-2.60 (-3.51 to -1.70)-2.86 (-3.76 to -1.95)-2.25 (-3.19 to -1.32)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -0.47 · 95% CI -1.75 to 0.82
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -0.88 · 95% CI -2.07 to 0.31
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -0.88 · 95% CI -2.03 to 0.28
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -1.13 · 95% CI -2.29 to 0.03
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -0.53 · 95% CI -1.71 to 0.65
SecondaryMean Change From Baseline at Week 16 in Primary Biliary Cholangitis-40 (PBC-40) Scale

PBC-40 is a disease-specific health-related quality of life (HRQoL) questionnaire for use in PBC participants. It consists of 40 questions arranged in 6 domains with 3 to 11 questions in each domain. Each question is scored from 1 (least impact) to 5 (greatest impact). All questions within a domain are summed to obtain individual domain score. Domains were: Symptoms (7 questions) with score range 7-35, Itch (3 questions) with score range 3-15, Fatigue (11 questions) with score range 11-55, Cognitive (6 questions) with score range 6-30, Emotional (3 questions) with score range 3-15, and Social (10 questions) with score range 10-50. Higher scores for individual domains represent a poor quality of life. Baseline is the assessment performed at Week 4 (V3) which is conducted prior to first dosing of randomized medication that evening. Change from Baseline was calculated as post-Baseline value minus Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline at Week 16 in Primary Biliary Cholangitis-40 (PBC-40) Scale
Scores on a scalePlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Symptoms0.2 (-1.0 to 1.4)0.4 (-1.3 to 2.2)0.7 (-0.8 to 2.3)-0.9 (-2.4 to 0.6)0.3 (-1.2 to 1.8)0.2 (-1.4 to 1.8)
Itch-2.3 (-3.3 to -1.4)-1.9 (-3.3 to -0.4)-2.6 (-3.9 to -1.3)-2.7 (-3.9 to -1.4)-3.4 (-4.6 to -2.1)-2.7 (-4.0 to -1.4)
Fatigue-1.8 (-4.0 to 0.4)-2.4 (-5.6 to 0.7)-1.1 (-3.8 to 1.7)1.7 (-1.0 to 4.5)-0.1 (-2.8 to 2.6)-1.8 (-4.6 to 1.1)
Cognitive-0.3 (-1.7 to 1.1)-0.3 (-2.4 to 1.8)-0.9 (-2.7 to 0.9)-0.1 (-1.9 to 1.6)0.1 (-1.6 to 1.9)-0.1 (-2.0 to 1.7)
Emotional-0.5 (-1.2 to 0.1)-1.4 (-2.4 to -0.4)-0.4 (-1.3 to 0.5)-0.6 (-1.5 to 0.3)-1.4 (-2.2 to -0.5)-0.6 (-1.5 to 0.3)
Social-0.8 (-2.3 to 0.8)-0.5 (-2.7 to 1.8)0.4 (-1.5 to 2.4)-0.6 (-2.5 to 1.3)-3.1 (-5.1 to -1.2)-1.0 (-3.0 to 1.0)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): 0.2 · 95% CI -1.9 to 2.3Symptoms
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): 0.5 · 95% CI -1.5 to 2.5Symptoms
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -1.1 · 95% CI -3.1 to 0.8Symptoms
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): 0.1 · 95% CI -1.8 to 2.0Symptoms
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.0 · 95% CI -2.0 to 1.9Symptoms
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): 0.5 · 95% CI -1.3 to 2.2Itch
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -0.3 · 95% CI -1.8 to 1.3Itch
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -0.3 · 95% CI -1.9 to 1.2Itch
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -1.0 · 95% CI -2.6 to 0.5Itch
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -0.3 · 95% CI -1.9 to 1.3Itch
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -0.6 · 95% CI -4.5 to 3.2Fatigue
  • Placebo vs GSK2330672 90 mg QD · Median difference (net): 0.7 · 95% CI -2.8 to 4.2Fatigue
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): 3.5 · 95% CI 0.0 to 7.0Fatigue
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): 1.7 · 95% CI -1.8 to 5.1Fatigue
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.0 · 95% CI -3.6 to 3.6Fatigue
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): 0.0 · 95% CI -2.5 to 2.6Cognitive
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -0.6 · 95% CI -2.9 to 1.7Cognitive
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): 0.2 · 95% CI -2.1 to 2.5Cognitive
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): 0.5 · 95% CI -1.8 to 2.8Cognitive
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.2 · 95% CI -2.2 to 2.5Cognitive
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -0.9 · 95% CI -2.1 to 0.4Emotional
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): 0.2 · 95% CI -0.9 to 1.3Emotional
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -0.1 · 95% CI -1.2 to 1.1Emotional
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -0.8 · 95% CI -1.9 to 0.3Emotional
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.0 · 95% CI -1.2 to 1.1Emotional
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): 0.3 · 95% CI -2.4 to 3.0Social
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): 1.2 · 95% CI -1.3 to 3.7Social
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): 0.2 · 95% CI -2.3 to 2.7Social
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -2.4 · 95% CI -4.8 to 0.1Social
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -0.2 · 95% CI -2.8 to 2.4Social
SecondaryMean Change From Baseline at Week 16 in Serum Alkaline Phosphatase (ALP) Concentrations, in Participants With High Risk of PBC Progression

Criteria for high risk of PBC progression is defined as serum ALP concentrations more than or equal to (\>=)1.67 times upper limit of normal (ULN) range and/or total bilirubin concentrations more than (\>)ULN at Day 1. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 (Day 1) or Visit 1 (Screening), excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · International units per Liter
Mean Change From Baseline at Week 16 in Serum Alkaline Phosphatase (ALP) Concentrations, in Participants With High Risk of PBC Progression
International units per LiterPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Mean Change From Baseline at Week 16 in Serum Alkaline Phosphatase (ALP) Concentrations, in Participants With High Risk of PBC Progression49.1 (-29.3 to 127.6)-57.7 (-179.6 to 64.3)-38.2 (-117.0 to 40.5)49.6 (-49.1 to 148.2)-29.2 (-136.7 to 78.3)19.1 (-97.7 to 136.0)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -106.8 · 95% CI -251.7 to 38.2
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -87.4 · 95% CI -198.5 to 23.8
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): 0.4 · 95% CI -125.6 to 126.5
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -78.3 · 95% CI -211.5 to 54.8
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -30.0 · 95% CI -170.7 to 110.7
SecondaryNumber of Participants With Serum ALP Concentrations Less Than (<)1.67 Times ULN and Total Bilirubin Concentrations Less Than or Equal to (<=) ULN at Week 16

Number of participants with ALP \< 1.67 times ULN and total bilirubin \<= ULN at Week 16 is presented. The endpoint was analyzed in Restricted High Risk Population.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Number of Participants With Serum ALP Concentrations Less Than (<)1.67 Times ULN and Total Bilirubin Concentrations Less Than or Equal to (<=) ULN at Week 16
ParticipantsPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Number of Participants With Serum ALP Concentrations Less Than (<)1.67 Times ULN and Total Bilirubin Concentrations Less Than or Equal to (<=) ULN at Week 16000001
SecondaryMean Change From Baseline at Week 16 in Serum Alanine Aminotransferase (ALT) Among Those With a High Risk of PBC Progression

Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including Treatment group and Baseline.

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · International Units per Liter
Mean Change From Baseline at Week 16 in Serum Alanine Aminotransferase (ALT) Among Those With a High Risk of PBC Progression
International Units per LiterPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Mean Change From Baseline at Week 16 in Serum Alanine Aminotransferase (ALT) Among Those With a High Risk of PBC Progression13.0 (-7.9 to 33.9)-8.4 (-39.5 to 22.7)0.3 (-20.7 to 21.2)-2.0 (-29.0 to 25.1)-13.5 (-42.8 to 15.9)13.2 (-17.4 to 43.7)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -21.4 · 95% CI -58.4 to 15.5
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -12.7 · 95% CI -41.9 to 16.4
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -15.0 · 95% CI -49.9 to 20.0
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -26.5 · 95% CI -63.3 to 10.4
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.2 · 95% CI -36.7 to 37.1
SecondaryMean Change From Baseline at Week 16 in Serum Aspartate Aminotransferase (AST) Among Those With a High Risk of PBC Progression

Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including Treatment group and Baseline.

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · International Units per Liter
Mean Change From Baseline at Week 16 in Serum Aspartate Aminotransferase (AST) Among Those With a High Risk of PBC Progression
International Units per LiterPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Mean Change From Baseline at Week 16 in Serum Aspartate Aminotransferase (AST) Among Those With a High Risk of PBC Progression13.96 (-4.55 to 32.46)-6.04 (-34.20 to 22.12)-10.75 (-28.90 to 7.40)-8.66 (-32.24 to 14.93)-17.72 (-42.77 to 7.34)8.16 (-18.72 to 35.04)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -20.00 · 95% CI -52.73 to 12.74
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -24.70 · 95% CI -50.80 to 1.39
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -22.61 · 95% CI -53.39 to 8.16
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -31.67 · 95% CI -63.44 to 0.09
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -5.79 · 95% CI -38.33 to 26.74
SecondaryMean Change From Baseline at Week 16 in Serum Gamma Glutamyl Transferase (GGT), Among Those With a High Risk of PBC Progression

Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · International Units per Liter
Mean Change From Baseline at Week 16 in Serum Gamma Glutamyl Transferase (GGT), Among Those With a High Risk of PBC Progression
International Units per LiterPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Mean Change From Baseline at Week 16 in Serum Gamma Glutamyl Transferase (GGT), Among Those With a High Risk of PBC Progression47.5 (-9.9 to 104.8)-58.5 (-142.5 to 25.5)-18.0 (-74.9 to 38.9)4.6 (-66.5 to 75.8)-18.4 (-93.6 to 56.8)-6.7 (-89.1 to 75.8)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -106.0 · 95% CI -205.1 to -6.8
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -65.5 · 95% CI -148.5 to 17.6
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -42.8 · 95% CI -136.5 to 50.9
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -65.8 · 95% CI -161.2 to 29.5
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -54.1 · 95% CI -153.6 to 45.3
SecondaryMean Change From Baseline at Week 16 in Total Bilirubin Concentration, Among Those With a High Risk of PBC Progression

Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · Micromoles per Liter
Mean Change From Baseline at Week 16 in Total Bilirubin Concentration, Among Those With a High Risk of PBC Progression
Micromoles per LiterPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Mean Change From Baseline at Week 16 in Total Bilirubin Concentration, Among Those With a High Risk of PBC Progression1.258 (-2.068 to 4.583)-4.841 (-9.693 to 0.011)-1.079 (-4.345 to 2.187)-0.975 (-5.150 to 3.201)-0.234 (-4.914 to 4.446)6.494 (1.622 to 11.365)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -6.099 · 95% CI -11.929 to -0.268
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -2.337 · 95% CI -6.962 to 2.289
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -2.232 · 95% CI -7.679 to 3.215
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -1.492 · 95% CI -7.413 to 4.430
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 5.236 · 95% CI -0.591 to 11.063
SecondaryMean Change From Baseline at Week 16 in Albumin Concentration, Among Those With a High Risk of PBC Progression

Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · Grams per Liter
Mean Change From Baseline at Week 16 in Albumin Concentration, Among Those With a High Risk of PBC Progression
Grams per LiterPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Mean Change From Baseline at Week 16 in Albumin Concentration, Among Those With a High Risk of PBC Progression0.0 (-1.2 to 1.3)-0.5 (-2.3 to 1.3)0.3 (-1.0 to 1.6)0.8 (-0.8 to 2.3)0.0 (-1.7 to 1.7)0.7 (-1.1 to 2.5)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -0.5 · 95% CI -2.7 to 1.6
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): 0.3 · 95% CI -1.5 to 2.1
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): 0.7 · 95% CI -1.2 to 2.7
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): 0.0 · 95% CI -2.1 to 2.0
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.7 · 95% CI -1.5 to 2.9
SecondaryMean Change From Baseline at Week 16 in Prothrombin International Normalized Ratio (INR), Among Those With a High Risk of PBC Progression

Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · Ratio
Mean Change From Baseline at Week 16 in Prothrombin International Normalized Ratio (INR), Among Those With a High Risk of PBC Progression
RatioPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Mean Change From Baseline at Week 16 in Prothrombin International Normalized Ratio (INR), Among Those With a High Risk of PBC Progression0.01 (-0.03 to 0.05)-0.01 (-0.06 to 0.04)-0.03 (-0.06 to 0.00)0.01 (-0.04 to 0.05)-0.02 (-0.07 to 0.02)-0.03 (-0.08 to 0.02)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -0.02 · 95% CI -0.08 to 0.04
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -0.04 · 95% CI -0.09 to 0.01
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): 0.00 · 95% CI -0.06 to 0.05
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -0.03 · 95% CI -0.09 to 0.02
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -0.04 · 95% CI -0.10 to 0.02
SecondaryMean Change From Baseline at Week 16 in Prothrombin Time, Among Those With a High Risk of PBC Progression

Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · Seconds
Mean Change From Baseline at Week 16 in Prothrombin Time, Among Those With a High Risk of PBC Progression
SecondsPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Mean Change From Baseline at Week 16 in Prothrombin Time, Among Those With a High Risk of PBC Progression-0.10 (-0.40 to 0.20)0.05 (-0.33 to 0.44)-0.21 (-0.47 to 0.05)0.02 (-0.33 to 0.37)-0.18 (-0.51 to 0.15)-0.17 (-0.55 to 0.22)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): 0.15 · 95% CI -0.33 to 0.63
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -0.11 · 95% CI -0.51 to 0.30
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): 0.12 · 95% CI -0.34 to 0.58
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -0.08 · 95% CI -0.54 to 0.38
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -0.07 · 95% CI -0.54 to 0.41
SecondaryNumber of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) -Main Study Period

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) -Main Study Period
ParticipantsPlacebo -Main Study PeriodGSK2330672 20 mg QD - Main Study PeriodGSK2330672 90 mg QD - Main Study PeriodGSK2330672 180 mg QD - Main Study PeriodGSK2330672 40 mg BID - Main Study PeriodGSK2330672 90 mg BID - Main Study Period
Any non-SAE171119241618
Any SAE001000
SecondaryNumber of Participants With Non-SAEs and SAEs -Final Study Period

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.

Time frame:
Up to 4 weeks
Reported as:
Count of participants · Participants
Number of Participants With Non-SAEs and SAEs -Final Study Period
ParticipantsPlacebo - Final Study PeriodGSK2330672 20 mg QD - Final Study PeriodGSK2330672 90 mg QD - Final Study PeriodGSK2330672 180 mg QD - Final Study PeriodGSK2330672 40 mg BID - Final Study PeriodGSK2330672 90 mg BID - Final Study Period
Any non-SAE268222
Any SAE000000
SecondaryNumber of Participants With Non-SAEs and SAEs - Follow-up Period

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.

Time frame:
Up to 4 weeks
Reported as:
Count of participants · Participants
Number of Participants With Non-SAEs and SAEs - Follow-up Period
ParticipantsPlacebo - Follow-upGSK2330672 20 mg QD - Follow-upGSK2330672 90 mg QD - Follow-upGSK2330672 180 mg QD - Follow-upGSK2330672 40 mg BID - Follow-upGSK2330672 90 mg BID - Follow-up
Any non-SAE000000
Any SAE010100
SecondaryNumber of Participants With Clinical Chemistry Data of Potential Clinical Importance

Blood samples were collected to measure analyze the following parameters: albumin, calcium, Glomerular filtration rate (GFR) from creatinine, glucose, potassium and sodium. Participants were counted in the worst case category that their value changes to (low, within range \[w/in\] or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (for example \[e.g.\], high to high), or whose value became within range, were recorded in the "To w/in Range or No Change" category. Participants were counted twice if the participant had values that changed "To Low" and "To High", so the percentages may not add to 100 percent (%). Only "To Low" and/or "To High" categories with potential clinical importance data have been presented.

Time frame:
At Weeks 8, 12, 16 and 20
Reported as:
Count of participants · Participants
Number of Participants With Clinical Chemistry Data of Potential Clinical Importance
ParticipantsPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Albumin, To Low, Week 8, n=36, 16, 21, 21, 22, 19000000
Albumin, To Low, Week 12, n=35, 16, 21, 23, 22, 21000000
Albumin, To Low, Week 16, n=35, 16, 21, 22, 21, 20000000
Albumin, To Low, Week 20, n=35, 16, 22, 22, 22, 21000000
Calcium, To Low, Week 8, n=36, 16, 21, 21, 22, 19000000
Calcium, To High, Week 8, n=36, 16, 21, 21, 22, 19000000
Calcium, To Low, Week 12, n=35, 16, 21, 23, 22, 21000000
Calcium, To High, Week 12, n=35, 16, 21, 23, 22, 21000000
Calcium, To Low, Week 16, n=35, 16, 21, 22, 21, 20000000
Calcium, To High, Week 16, n=35, 16, 21, 22, 21, 20000000
Calcium, To Low, Week 20, n=35, 16, 22, 22, 22, 21000000
Calcium, To High, Week 20, n=35, 16, 22, 22, 22, 21100000
GFR, To Low, Week 8, n=36, 16, 21, 21, 22, 19000000
GFR, To Low, Week 12, n=35, 15, 21, 23, 22, 21000000
GFR, To Low, Week 16, n=35, 16, 21, 22, 21, 21000000
GFR, To Low, Week 20, n=35, 16, 22, 22, 22, 21000100
Glucose ,To Low, Week 8, n=36, 16, 21, 21, 22, 19000000
Glucose ,To High, Week 8, n=36, 16, 21, 21, 22, 19100001
Glucose ,To Low, Week 12, n=35, 16, 21, 23, 22, 21000000
Glucose, To High, Week 12, n=35, 16, 21, 23, 22, 21000000
Glucose ,To Low, Week 16, n=35, 16, 21, 22, 21,20000000
Glucose, To High, Week 16, n=35, 16, 21, 22, 21, 20000000
Glucose ,To Low, Week 20, n=35, 16, 22, 22, 22, 21000000
Glucose, To High, Week 20, n=35, 16, 22, 22, 22, 21100000
Potassium,To Low, Week 8, n=36, 16, 21, 21, 22, 19000000
Potassium, To High, Week 8, n=36, 16, 21, 21, 22, 19000000
Potassium,To Low, Week 12, n=35, 16, 21, 23, 22, 21000000
Potassium, To High, Week 12, n=35, 16, 21, 23, 22, 21000000
Potassium,To Low, Week 16, n=35, 16, 21, 22, 21, 20000000
Potassium, To High, Week 16, n=35, 16, 21, 22, 21, 20000000
Potassium,To Low, Week 20, n=35, 16, 22, 22, 22, 21000000
Potassium, To High, Week 20, n=35, 16, 22,22, 22, 21000000
Sodium, To Low, Week 8, n=36, 16, 21, 21, 22, 19000000
Sodium, To High, Week 8, n=36, 16, 21, 21, 22, 19000000
Sodium, To Low, Week 12, n=35, 16, 21, 23, 22, 21000000
Sodium, To High, Week 12, n=35, 16, 21, 23, 22, 21000000
Sodium, To Low, Week 16, n=35, 16, 21, 22, 21, 20000000
Sodium, To High, Week 16, n=35, 16, 21, 22, 21, 20001000
Sodium, To Low, Week 20, n=35, 16, 22, 22, 22, 21000000
Sodium, To High, Week 20, n=35, 16, 22, 22, 22, 21000000
SecondaryNumber of Participants With Hematology Data of Potential Clinical Importance

Blood samples were collected to analyze the following parameters: hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. Participants were counted in the worst case category that their value changes to (low, w/in or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., high to high), or whose value became within range, were recorded in the "To w/in Range or No Change" category. Participants were counted twice if the participant had values that changed "To Low" and "To High", so the percentages may not add to 100%. Only "To Low" and/or "To High" categories with potential clinical importance data have been presented.

Time frame:
At Weeks 8, 12, 16 and 20
Reported as:
Count of participants · Participants
Number of Participants With Hematology Data of Potential Clinical Importance
ParticipantsPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Hematocrit, To High, Week 8,n=36, 16, 21, 21, 22, 19000000
Hematocrit, To High, Week 12, n=33, 15, 21, 23, 22, 20000000
Hematocrit, To High, Week 16, n=35, 15, 21, 22, 21, 21000000
Hematocrit, To High, Week 20, n=34, 16, 22, 22, 22, 20000000
Hemoglobin, To High, Week 8,n=36,16, 21, 21, 22,19000000
Hemoglobin, To High, Week 12, n=33,15, 21, 23, 22, 20000000
Hemoglobin, To High, Week 16, n=35, 15, 21, 22, 21, 21000000
Hemoglobin, To High, Week 20, n=34,16, 22, 22, 22, 20000000
Leukocytes, To Low, Week 8, n=36,15, 21, 21, 22,19100010
Leukocytes,To High, Week 8, n=36,15, 21, 21, 22,19000000
Leukocytes, To Low, Week 12, n=33,15, 21, 23, 22, 20111000
Leukocytes,To High, Week 12, n=33,15,21,23, 22, 20000000
Leukocytes, To Low, Week 16, n=34, 15, 21, 22, 20, 21103110
Leukocytes,To High, Week 16, n=34, 15, 21, 22, 20, 21000000
Leukocytes, To Low, Week 20, n=34,16, 22, 21, 22, 19011000
Leukocytes, To High, Week 20, n=34,16, 22, 21, 22, 19000000
Lymphocytes, To Low, Week 8, n=35,15, 21, 21, 22, 19200000
Lymphocytes, To Low, Week 12, n=32,15,21,23, 22, 20100200
Lymphocytes, To Low, Week 16, n=34, 15, 21, 22, 20, 21000100
Lymphocytes, To Low, Week 20, n=34,16, 22, 21, 22, 19001000
Neutrophils, To Low, Week 8,n=35,15, 21, 21, 22, 19110111
Neutrophils, To Low, Week 12, n=32, 15, 21, 23, 22, 20010101
Neutrophils, To Low, Week 16, n=34, 15, 21, 22, 20, 21102010
Neutrophils, To Low, Week 20, n=34,16, 22, 21, 22,19001000
Platelets, To Low, Week 8,n=36,15, 20, 21, 22,19000000
Platelets, To High, Week 8,n=36,15, 20, 21, 22, 19000000
Platelets, To Low, Week 12, n=33,14,19, 23, 22, 20000001
Platelets,To High, Week 12, n=33, 14, 19, 23, 22, 20000000
Platelets, To Low, Week 16, n=35, 14, 19, 22, 21, 21100001
Platelets,To High, Week 16, n=35, 14, 19, 22, 21, 21100000
Platelets, To Low, Week 20, n=33,16, 21, 21, 22, 20000000
Platelets,To High, Week 20, n=33, 16, 21, 21, 22, 20000000
SecondaryNumber of Participants With Abnormal 12-Lead Electrocardiogram (ECG) Parameters

A 12-lead ECG was recorded with the participant in a semi-supine position. 12-lead ECGs were obtained by using an automated ECG machine. Data for abnormal, not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame:
At Weeks 8, 12, 16 and 20
Reported as:
Count of participants · Participants
Number of Participants With Abnormal 12-Lead Electrocardiogram (ECG) Parameters
ParticipantsPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Abnormal, NCS, Week 8, n=36, 16, 21, 21, 22,191021784
Abnormal, CS, Week 8, n=36, 16, 21, 21, 22, 19000100
Abnormal, NCS, Week 12, n= 35, 16, 20, 23, 22, 21933884
Abnormal, CS, Week 12, n=35, 16, 20, 23, 22, 21000000
Abnormal, NCS, Week 16, n= 35, 16, 21, 21, 22 ,21932574
Abnormal, CS, Week 16, n=35, 16, 21, 21, 22, 21000000
Abnormal, NCS, Week 20, n=35, 16, 22, 22, 22, 20832783
Abnormal, CS, Week 20, n=35, 16, 22, 22, 22, 20000000
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 20
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercury (mmHg)PlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
SBP-3.3 ± 13.33-2.1 ± 11.470.1 ± 12.780.7 ± 10.42-0.3 ± 15.162.0 ± 15.43
DBP-1.3 ± 8.990.3 ± 7.75-0.3 ± 9.16-0.7 ± 5.512.5 ± 8.642.3 ± 7.23
SecondaryChange From Baseline in Pulse Rate

Pulse rate was measured in a semi-supine position after 5 minutes of rest. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and Week 20
Reported as:
Mean · Beats per minute
Change From Baseline in Pulse Rate
Beats per minutePlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Change From Baseline in Pulse Rate1.5 ± 7.19-2.6 ± 10.351.2 ± 10.91-0.2 ± 7.933.4 ± 8.920.5 ± 8.03
SecondaryChange From Baseline in Gastrointestinal Symptom Rating Scale (GSRS) Assessment

GSRS is a validated scale used to assess gastrointestinal symptoms experienced by participants over the preceding 5 to 7 days. GSRS was measured for all 5 domains: Average Diarrhea Syndrome Score, Average Indigestion Syndrome Score, Average Constipation Syndrome Score, Average Abdominal Pain Syndrome Score, Average Reflux Syndrome Score. All individual domains are scored on a 7-point Likert scale ranging from 1(not at all) to 7(extremely). Higher score indicate more severe symptoms. The Average Total GSRS score was mean of these 5 domains and ranges from 1 to 7. Higher score indicates worst possible degree of symptoms. The responses summarized at each visit are those given during the week prior to the visit, with exception of Day 1. Baseline is the most recent assessment completed by participant prior to randomization. Change from Baseline was calculated as post-Baseline value minus the Baseline value. Data has been presented for each domain along with the average Total GSRS score.

Time frame:
Baseline and Week 20
Reported as:
Mean · Scores on a scale
Change From Baseline in Gastrointestinal Symptom Rating Scale (GSRS) Assessment
Scores on a scalePlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Average Diarrhea Syndrome Score0.22 ± 1.3430.15 ± 1.5870.23 ± 1.180-0.13 ± 0.637-0.23 ± 1.7290.22 ± 1.565
Average Indigestion Syndrome Score-0.01 ± 1.1380.09 ± 0.865-0.03 ± 0.811-0.14 ± 0.820-0.31 ± 1.046-0.54 ± 1.007
Average Constipation Syndrome Score-0.03 ± 1.045-0.15 ± 0.9890.32 ± 1.370-0.02 ± 0.934-0.32 ± 1.215-0.37 ± 0.772
Average Abdominal Pain Syndrome Score-0.05 ± 1.0740.06 ± 0.712-0.02 ± 1.000-0.06 ± 0.629-0.08 ± 0.885-0.25 ± 0.904
Average Reflux Syndrome Score-0.09 ± 1.208-0.13 ± 0.619-0.20 ± 1.332-0.26 ± 0.664-0.16 ± 0.762-0.43 ± 0.847
Average Total Score0.01 ± 0.8300.02 ± 0.6680.07 ± 0.802-0.11 ± 0.433-0.23 ± 0.690-0.28 ± 0.695
SecondaryNumber of Participants With Mean Worst Daily Itch Score of <4 at Week 16

Participants were required to score the severity of their itching using a 0-10 NRS where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Number of participants with Mean Worst Daily Itch Score of \<4 at Week 16 is presented.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Number of Participants With Mean Worst Daily Itch Score of <4 at Week 16
ParticipantsPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Number of Participants With Mean Worst Daily Itch Score of <4 at Week 16211314181814
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Odds ratio (or): 2.89 · 95% CI 0.69 to 12.02Analysis was performed using Logistic regression. No covariates were used.
  • Placebo vs GSK2330672 90 mg QD · Odds ratio (or): 1.56 · 95% CI 0.48 to 5.02Analysis was performed using Logistic regression. No covariates were used.
  • Placebo vs GSK2330672 180 mg QD · Odds ratio (or): 3.00 · 95% CI 0.84 to 10.76Analysis was performed using Logistic regression. No covariates were used.
  • Placebo vs GSK2330672 40 mg BID · Odds ratio (or): 3.00 · 95% CI 0.84 to 10.76Analysis was performed using Logistic regression. No covariates were used.
  • Placebo vs GSK2330672 90 mg BID · Odds ratio (or): 1.33 · 95% CI 0.43 to 4.13Analysis was performed using Logistic regression. No covariates were used.
SecondaryNumber of Participants With Improvement of >= 30 Percent (%) in the Mean Worst Daily Itch Score at Week 16 From Baseline

Participants were required to score the severity of their itching using a 0-10 NRS where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Baseline is the most recent assessment completed by the participant prior to randomization. Number of participants with improvement of \>= 30% in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented.

Time frame:
Baseline and At Week 16
Reported as:
Count of participants · Participants
Number of Participants With Improvement of >= 30 Percent (%) in the Mean Worst Daily Itch Score at Week 16 From Baseline
ParticipantsPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Number of Participants With Improvement of >= 30 Percent (%) in the Mean Worst Daily Itch Score at Week 16 From Baseline17915141514
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Odds ratio (or): 1.36 · 95% CI 0.41 to 4.47Analysis was performed using Logistic regression. No covariates were used.
  • Placebo vs GSK2330672 90 mg QD · Odds ratio (or): 3.18 · 95% CI 0.95 to 10.65Analysis was performed using Logistic regression. No covariates were used.
  • Placebo vs GSK2330672 180 mg QD · Odds ratio (or): 1.85 · 95% CI 0.62 to 5.53Analysis was performed using Logistic regression. No covariates were used.
  • Placebo vs GSK2330672 40 mg BID · Odds ratio (or): 2.27 · 95% CI 0.74 to 6.92Analysis was performed using Logistic regression. No covariates were used.
  • Placebo vs GSK2330672 90 mg BID · Odds ratio (or): 2.12 · 95% CI 0.69 to 6.51Analysis was performed using Logistic regression. No covariates were used.
SecondaryNumber of Participants With Improvement of >=2 in the Mean Worst Daily Itch Score at Week 16 From Baseline

Participants were required to score the severity of their itching using a 0-10 NRS where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Baseline is the most recent assessment completed by the participant prior to randomization. Number of participants with improvement of \>=2 in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented.

Time frame:
Baseline and At Week 16
Reported as:
Count of participants · Participants
Number of Participants With Improvement of >=2 in the Mean Worst Daily Itch Score at Week 16 From Baseline
ParticipantsPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Number of Participants With Improvement of >=2 in the Mean Worst Daily Itch Score at Week 16 From Baseline1461291312
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Odds ratio (or): 0.90 · 95% CI 0.27 to 3.04Analysis was performed using Logistic regression. No covariates were used.
  • Placebo vs GSK2330672 90 mg QD · Odds ratio (or): 2.25 · 95% CI 0.73 to 6.91Analysis was performed using Logistic regression. No covariates were used.
  • Placebo vs GSK2330672 180 mg QD · Odds ratio (or): 1.04 · 95% CI 0.35 to 3.08Analysis was performed using Logistic regression. No covariates were used.
  • Placebo vs GSK2330672 40 mg BID · Odds ratio (or): 2.17 · 95% CI 0.73 to 6.42Analysis was performed using Logistic regression. No covariates were used.
  • Placebo vs GSK2330672 90 mg BID · Odds ratio (or): 2.00 · 95% CI 0.67 to 5.99Analysis was performed using Logistic regression. No covariates were used.
SecondaryPercentage of Responder Days With Worst Daily Itch Score of <4

Percentage of Responder Days with Worst Daily Itch score was calculated as: (number of days response from Visit 3+1 to Visit 6-1 divided by number of days from Visit 3+1 to Visit 6-1 with worst daily itch scores available) times 100. Days for which no worst daily itch score was available did not contribute to either the numerator or the denominator. Analysis was performed using ANCOVA model including treatment group. Percentage of responder days with Worst Daily Itch Score of \<4 is presented.

Time frame:
Up to Week 16
Reported as:
Least squares mean · Percentage of days
Percentage of Responder Days With Worst Daily Itch Score of <4
Percentage of daysPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Percentage of Responder Days With Worst Daily Itch Score of <440.32 (28.79 to 51.86)58.53 (41.23 to 75.83)51.38 (36.95 to 65.81)58.76 (45.45 to 72.08)65.80 (51.37 to 80.23)53.58 (38.83 to 68.34)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): 18.21 · 95% CI -2.59 to 39.00
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): 11.05 · 95% CI -7.42 to 29.53
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): 18.44 · 95% CI 0.82 to 36.06
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): 25.48 · 95% CI 7.00 to 43.95
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 13.26 · 95% CI -5.47 to 31.99
SecondaryPercentage of Responder Days With Improvement of >= 30% in the Mean Worst Daily Itch Score at Week 16 From Baseline

Percentage of Responder Days with Worst Daily Itch score was calculated as: (number of days response from Visit 3+1 to Visit 6-1 divided by number of days from Visit 3+1 to Visit 6-1 with worst daily itch scores available) times 100. Days for which no worst daily itch score was available did not contribute to either the numerator or the denominator. Analysis was performed using ANCOVA model including treatment group. Baseline is the most recent assessment completed by the participant prior to randomization. Percentage of responder days with improvement of \>= 30% in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented..

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · Percentage of days
Percentage of Responder Days With Improvement of >= 30% in the Mean Worst Daily Itch Score at Week 16 From Baseline
Percentage of daysPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Percentage of Responder Days With Improvement of >= 30% in the Mean Worst Daily Itch Score at Week 16 From Baseline38.46 (27.30 to 49.61)53.44 (36.71 to 70.18)45.43 (31.47 to 59.39)50.23 (37.35 to 63.12)60.29 (46.33 to 74.25)60.03 (45.76 to 74.31)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): 14.99 · 95% CI -5.13 to 35.10
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): 6.97 · 95% CI -10.90 to 24.84
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): 11.78 · 95% CI -5.27 to 28.82
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): 21.83 · 95% CI 3.96 to 39.70
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 21.58 · 95% CI 3.46 to 39.69
SecondaryPercentage of Responder Days With Improvement of >=2 in the Mean Worst Daily Itch Score at Week 16 From Baseline

Percentage of Responder Days with Worst Daily Itch was calculated as: (number of days response from Visit 3+1 to Visit 6-1 divided by number of days from Visit 3+1 to Visit 6-1 with worst daily itch scores available) times 100. Days for which no worst daily itch score was available did not contribute to either the numerator or the denominator. Analysis was performed using ANCOVA model including treatment group. Baseline is the most recent assessment completed by the participant prior to randomization. Percentage of responder days with improvement of \>=2 in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented.

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · Percentage of days
Percentage of Responder Days With Improvement of >=2 in the Mean Worst Daily Itch Score at Week 16 From Baseline
Percentage of daysPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Percentage of Responder Days With Improvement of >=2 in the Mean Worst Daily Itch Score at Week 16 From Baseline31.56 (19.96 to 43.16)37.71 (20.31 to 55.11)38.82 (24.31 to 53.33)40.69 (27.29 to 54.08)51.49 (36.98 to 66.00)58.60 (43.76 to 73.43)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): 6.15 · 95% CI -14.76 to 27.06
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): 7.26 · 95% CI -11.32 to 25.84
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): 9.13 · 95% CI -8.59 to 26.85
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): 19.94 · 95% CI 1.36 to 38.51
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 27.04 · 95% CI 8.20 to 45.87
SecondaryChange From Baseline in the Mean Daily Sleep Score at Week 16

Mean Daily Sleep Score is defined as the average of the daily sleep scores provided in the 7 days prior to the relevant visit. Participants sleep quality was recorded in an electronic diary each morning using a 0-10 NRS in which 0: good sleep to 10:worst possible sleep. Higher score indicates worse possible sleep. Baseline is the average of the scores in the 7 days prior to the Week 4 (V3) visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in the Mean Daily Sleep Score at Week 16
Scores on a scalePlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Change From Baseline in the Mean Daily Sleep Score at Week 16-1.39 (-2.06 to -0.72)-1.66 (-2.64 to -0.67)-1.87 (-2.75 to -0.99)-1.85 (-2.69 to -1.01)-2.35 (-3.19 to -1.50)-1.69 (-2.57 to -0.81)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -0.27 · 95% CI -1.46 to 0.92
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -0.48 · 95% CI -1.58 to 0.62
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -0.46 · 95% CI -1.53 to 0.61
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -0.96 · 95% CI -2.03 to 0.12
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -0.30 · 95% CI -1.40 to 0.80
SecondaryChange From Baseline in the Mean Daily Fatigue Score at Week 16

Mean Daily Fatigue Score is defined as the average of the daily fatigue scores provided in the 7 days prior to the relevant visit. Participants fatigue level was recorded in an electronic diary each evening using a 0-10 NRS in which 0: no fatigue to 10:worst possible fatigue. Higher score indicates worse possible fatigue. Baseline is the average of the scores in the 7 days prior to the Week 4 (V3) visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in the Mean Daily Fatigue Score at Week 16
Scores on a scalePlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Change From Baseline in the Mean Daily Fatigue Score at Week 16-0.79 (-1.39 to -0.18)-1.18 (-2.08 to -0.27)-1.19 (-2.00 to -0.37)-1.04 (-1.81 to -0.28)-1.20 (-1.97 to -0.44)-1.07 (-1.86 to -0.29)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -0.39 · 95% CI -1.49 to 0.71
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -0.40 · 95% CI -1.41 to 0.61
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -0.26 · 95% CI -1.24 to 0.72
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -0.42 · 95% CI -1.39 to 0.56
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -0.29 · 95% CI -1.28 to 0.70
SecondaryChange From Baseline in the Five-Dimensional (5-D) Itch Scale at Week 16

The 5-D itch scale had been developed as a brief, single page, instrument for the multidimensional quantification of itch that is sensitive to change over time. It has data to support its validity in a population of participants with pruritus and covers five dimensions of itch experienced by participants: duration, degree, direction, disability and distribution. Each domain was scored on a 5-point scale, ranging from 1 (Not present/resolved/never) to 5 (unbearable/getting worse/always), higher scores indicates worst itching. The scores of each of five domains were achieved separately and then summed together to obtain a total 5-D score. A total 5-D scores potentially ranged between 5 (no pruritus) and 25 (most severe pruritus) where higher score indicates worse possible itching. Baseline is assessment performed at Week 4 (V3) which is conducted prior to first dosing of randomized medication that evening. Change from Baseline was calculated as post-Baseline value minus Baseline value.

Time frame:
Baseline and at Week 16
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in the Five-Dimensional (5-D) Itch Scale at Week 16
Scores on a scalePlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Duration-0.8 (-1.1 to -0.4)-0.9 (-1.3 to -0.4)-0.4 (-0.8 to 0.0)-1.2 (-1.6 to -0.8)-0.6 (-1.0 to -0.2)-0.7 (-1.1 to -0.3)
Degree-0.7 (-1.0 to -0.4)-0.9 (-1.4 to -0.5)-0.7 (-1.1 to -0.3)-0.7 (-1.2 to -0.3)-0.9 (-1.3 to -0.5)-0.8 (-1.2 to -0.4)
Direction-0.7 (-1.1 to -0.3)-0.7 (-1.3 to -0.1)-0.7 (-1.2 to -0.2)-0.9 (-1.4 to -0.4)-1.1 (-1.6 to -0.6)-0.7 (-1.2 to -0.2)
Disability-0.4 (-0.7 to 0.0)-0.8 (-1.4 to -0.2)-0.5 (-1.0 to 0.0)-0.7 (-1.2 to -0.2)-0.7 (-1.2 to -0.2)-0.7 (-1.2 to -0.1)
Distribution-0.4 (-0.7 to -0.1)-0.7 (-1.2 to -0.2)-0.7 (-1.1 to -0.3)-0.9 (-1.3 to -0.5)-0.7 (-1.2 to -0.3)-0.6 (-1.0 to -0.2)
5-D Itch Total Score-3.0 (-4.2 to -1.7)-4.0 (-5.9 to -2.0)-3.0 (-4.7 to -1.3)-4.4 (-6.0 to -2.7)-3.8 (-5.4 to -2.2)-3.5 (-5.2 to -1.8)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -0.1 · 95% CI -0.7 to 0.5Duration
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): 0.4 · 95% CI -0.2 to 0.9Duration
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -0.4 · 95% CI -1.0 to 0.1Duration
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): 0.2 · 95% CI -0.3 to 0.7Duration
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.1 · 95% CI -0.4 to 0.6Duration
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -0.2 · 95% CI -0.8 to 0.3Degree
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): 0.0 · 95% CI -0.5 to 0.5Degree
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -0.1 · 95% CI -0.6 to 0.5Degree
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -0.2 · 95% CI -0.7 to 0.3Degree
  • Placebo vs GSK2330672 90 mg BID · Median difference (net): -0.1 · 95% CI -0.6 to 0.4Degree
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): 0.0 · 95% CI -0.7 to 0.7Direction
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): 0.0 · 95% CI -0.7 to 0.6Direction
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -0.2 · 95% CI -0.8 to 0.5Direction
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -0.4 · 95% CI -1.0 to 0.2Direction
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): 0.0 · 95% CI -0.6 to 0.6Direction
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -0.4 · 95% CI -1.1 to 0.3Disability
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -0.2 · 95% CI -0.8 to 0.5Disability
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -0.3 · 95% CI -1.0 to 0.3Disability
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -0.3 · 95% CI -1.0 to 0.3Disability
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -0.3 · 95% CI -1.0 to 0.3Disability
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -0.3 · 95% CI -0.9 to 0.3Distribution
  • Placebo vs GSK2330672 90 mg QD · Median difference (net): -0.3 · 95% CI -0.9 to 0.2Distribution
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -0.5 · 95% CI -1.0 to 0.0Distribution
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -0.3 · 95% CI -0.9 to 0.2Distribution
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -0.2 · 95% CI -0.7 to 0.3Distribution
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -1.0 · 95% CI -3.3 to 1.35-D Itch Total Score
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -0.1 · 95% CI -2.2 to 2.15-D Itch Total Score
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -1.4 · 95% CI -3.5 to 0.75-D Itch Total Score
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -0.9 · 95% CI -3.0 to 1.25-D Itch Total Score
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -0.6 · 95% CI -2.7 to 1.65-D Itch Total Score
SecondaryMean Change From Baseline at Week 16 in Serum Total Bile Acid Concentration

Blood samples were collected for evaluating total bile acid concentration as a biomarker of PBC. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and at Week 16
Reported as:
Mean · Micromoles per Liter
Mean Change From Baseline at Week 16 in Serum Total Bile Acid Concentration
Micromoles per LiterPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Mean Change From Baseline at Week 16 in Serum Total Bile Acid Concentration-4.274 ± 20.0163-0.469 ± 6.5466-3.878 ± 40.1857-1.114 ± 6.9359-2.133 ± 8.93087.379 ± 38.8282
SecondaryMean Change From Baseline at Week 16 in Serum 7-alpha Hydroxy-4-cholesten-3-one (C4)

Blood samples were collected for evaluating C4 concentration as a marker of bile acid synthesis. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline and at Week 16
Reported as:
Mean · Micrograms per Liter
Mean Change From Baseline at Week 16 in Serum 7-alpha Hydroxy-4-cholesten-3-one (C4)
Micrograms per LiterPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Mean Change From Baseline at Week 16 in Serum 7-alpha Hydroxy-4-cholesten-3-one (C4)4.746 ± 11.564410.703 ± 24.604511.452 ± 16.637129.488 ± 38.758458.674 ± 59.483340.629 ± 36.2769
SecondaryPlasma Concentration of GSK2330672 After Sparse Sampling

Blood samples were collected for measurement of plasma GSK2330672 concentration.

Time frame:
At Week 4 (between 1 and 3 hours post-dose) and At Weeks 8, 12 and 16 (between 1 and 3 hours post-dose, and between 5 and 8 hours post-dose)
Reported as:
Mean · Picograms per milliliter
Plasma Concentration of GSK2330672 After Sparse Sampling
Picograms per milliliterGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Week 4, Between 1 and 3 hours post-dose, n=6, 2, 7, 0, 45.00 ± NA5.00 ± NA32.71 ± 73.325—5.00 ± NA
Week 8, Between 1 and 3 hours post-dose, n=16, 21, 20, 22, 17358.04 ± 665.685958.81 ± 1563.2652327.58 ± 3737.965453.45 ± 967.4242908.06 ± 5106.895
Week 8, Between 5 and 8 hours post-dose, n=14, 17, 18, 21, 16300.04 ± 356.268820.87 ± 1143.0232234.28 ± 3420.442339.74 ± 357.9141990.89 ± 4061.978
Week 12, Between 1 and 3 hours post-dose, n=14, 19, 17, 20, 14447.88 ± 1160.5181594.16 ± 3133.3702060.51 ± 2888.033419.47 ± 774.3213531.36 ± 6296.828
Week 12, Between 5 and 8 hours post-dose, n=14, 16, 17, 20, 13341.39 ± 638.3591084.00 ± 1353.0892569.00 ± 3727.883303.83 ± 300.7162197.16 ± 3604.704
Week 16, Between 1 and 3 hours post-dose, n=3, 5, 4, 2, 5394.00 ± 162.151864.26 ± 1045.4673328.50 ± 3185.646338.50 ± 236.881703.60 ± 756.010
Week 16, Between 5 and 8 hours post-dose, n=3, 3, 4, 2, 5296.33 ± 118.154578.00 ± 651.2631940.50 ± 1128.203364.50 ± 217.082869.40 ± 1148.331
Post-hocMean Change From Baseline in Monthly Itch Score

Participants were required to score severity of their itching each morning and evening using a 0-10 NRS where 0(no itching) and 10(worst imaginable itching). The worst of these 2 scores was Worst Daily Itch Score. For each week, mean Worst Daily Itch Score was calculated to form Mean Worst Daily Itch Score. The Monthly Itch Score was defined as worst weekly score (e.g., Mean Worst Daily Itch Score) for that month. The monthly itch score ranges from 0 to 10, higher score indicates worst imaginable itching. Baseline is average of scores in the 7 days prior to Week 4 (Visit 3 \[V3\]). Change from Baseline was calculated as post-Baseline value minus Baseline value. Mean change from Baseline in monthly itch score over 12 week treatment period is presented. Analysis was performed on change in Monthly Itch Scores over 12 week treatment period using Mixed model repeated measures (MMRM) with Baseline itch, treatment group, visit and a treatment group\*visit interaction as covariates in the model.

Time frame:
Baseline and up to Week 12
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in Monthly Itch Score
Scores on a scalePlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Mean Change From Baseline in Monthly Itch Score-0.46 (-1.01 to 0.08)-1.17 (-1.99 to -0.35)-1.08 (-1.77 to -0.39)-1.36 (-2.03 to -0.69)-1.63 (-2.32 to -0.93)-1.41 (-2.13 to -0.7)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Mean difference (net): -0.71 · 95% CI -1.69 to 0.28
  • Placebo vs GSK2330672 90 mg QD · Mean difference (net): -0.62 · 95% CI -1.49 to 0.26
  • Placebo vs GSK2330672 180 mg QD · Mean difference (net): -0.9 · 95% CI -1.76 to -0.03
  • Placebo vs GSK2330672 40 mg BID · Mean difference (net): -1.16 · 95% CI -2.05 to -0.28
  • Placebo vs GSK2330672 90 mg BID · Mean difference (net): -0.95 · 95% CI -1.85 to -0.06
Post-hocRatio to Baseline in Total Serum Bile Acid Concentration

Blood samples were collected for evaluation of total bile acid concentration as a biomarker of PBC. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 (Day 1) or Visit 1 (Screening), excluding unscheduled visits. Ratio to Baseline was defined as the geometric mean of post-Baseline visit value divided by the geometric mean of Baseline value. Values were log-transformed and mean change from Baseline on the log-scale was calculated over the 12 week treatment period. Analysis was performed on change in total serum bile acid concentration on the log-scale over the 12 week treatment period using Mixed model repeated measures (MMRM) with log-transformed Baseline total serum bile acid, visit, treatment group, a log-transformed Baseline total serum bile acid\*visit interaction, and a treatment group\*visit interaction used as covariates in the model. Afterwards, values were back-transformed to the original scale. Ratios of geometric means are presented.

Time frame:
Baseline and up to Week 12
Reported as:
Least squares mean · Ratio
Ratio to Baseline in Total Serum Bile Acid Concentration
RatioPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Ratio to Baseline in Total Serum Bile Acid Concentration1.01 (0.801 to 1.273)0.977 (0.688 to 1.386)1.182 (0.874 to 1.6)0.918 (0.687 to 1.226)0.697 (0.519 to 0.938)0.833 (0.616 to 1.127)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Least square (ls) mean ratio: 0.967 · 95% CI 0.635 to 1.471
  • Placebo vs GSK2330672 90 mg QD · Ls mean ratio: 1.17 · 95% CI 0.8 to 1.712
  • Placebo vs GSK2330672 180 mg QD · Ls mean ratio: 0.909 · 95% CI 0.627 to 1.316
  • Placebo vs GSK2330672 40 mg BID · Ls mean ratio: 0.69 · 95% CI 0.474 to 1.005
  • Placebo vs GSK2330672 90 mg BID · Ls mean ratio: 0.825 · 95% CI 0.564 to 1.207
Post-hocRatio to Baseline in Serum 7-alpha-hydroxy-4-cholesten-3-one (C4) Concentration

Blood samples were collected for evaluation of C4 concentration as a marker of bile acid synthesis. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 (Day 1) or Visit 1 (Screening), excluding unscheduled visits. Ratio to Baseline was defined as the geometric mean of post-Baseline visit value divided by the geometric mean of Baseline value. Values were log-transformed and mean change from Baseline on the log-scale was calculated over the 12 week treatment period. Analysis was performed on change in C4 on the log-scale over the 12 week treatment period using Mixed model repeated measures (MMRM) with log-transformed Baseline C4, visit, treatment group, a log-transformed Baseline C4\*visit interaction, and a treatment group\*visit interaction used as covariates in the model. Afterwards, values were back-transformed to the original scale. Ratios of geometric means are presented.

Time frame:
Baseline and up to Week 12
Reported as:
Least squares mean · Ratio
Ratio to Baseline in Serum 7-alpha-hydroxy-4-cholesten-3-one (C4) Concentration
RatioPlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BID
Ratio to Baseline in Serum 7-alpha-hydroxy-4-cholesten-3-one (C4) Concentration1.158 (0.937 to 1.431)1.579 (1.151 to 2.166)2.374 (1.812 to 3.109)2.846 (2.192 to 3.694)3.622 (2.753 to 4.764)3.127 (2.385 to 4.101)
Statistical analysis
  • Placebo vs GSK2330672 20 mg QD · Ls mean ratio: 1.363 · 95% CI 0.932 to 1.995
  • Placebo vs GSK2330672 90 mg QD · Ls mean ratio: 2.05 · 95% CI 1.456 to 2.887
  • Placebo vs GSK2330672 180 mg QD · Ls mean ratio: 2.457 · 95% CI 1.758 to 3.436
  • Placebo vs GSK2330672 40 mg BID · Ls mean ratio: 3.128 · 95% CI 2.206 to 4.435
  • Placebo vs GSK2330672 90 mg BID · Ls mean ratio: 2.701 · 95% CI 1.915 to 3.81

Adverse events

Collected over Non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to 12 weeks during Main study period; up to 4 weeks during Final study period and up to 4 weeks during Follow-up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Main Study Period0/36 (0%)0/36 (0%)17/36 (47.2%)
GSK2330672 20 mg QD - Main Study Period0/16 (0%)0/16 (0%)11/16 (68.8%)
GSK2330672 90 mg QD - Main Study Period0/23 (0%)1/23 (4.3%)19/23 (82.6%)
GSK2330672 180 mg QD - Main Study Period0/27 (0%)0/27 (0%)24/27 (88.9%)
GSK2330672 40 mg BID - Main Study Period0/23 (0%)0/23 (0%)16/23 (69.6%)
GSK2330672 90 mg BID - Main Study Period0/22 (0%)0/22 (0%)18/22 (81.8%)
Placebo - Final Study Period0/35 (0%)0/35 (0%)2/35 (5.7%)
GSK2330672 20 mg QD - Final Study Period0/16 (0%)0/16 (0%)6/16 (37.5%)
GSK2330672 90 mg QD - Final Study Period0/19 (0%)0/19 (0%)8/19 (42.1%)
GSK2330672 180 mg QD - Final Study Period0/19 (0%)0/19 (0%)2/19 (10.5%)
GSK2330672 40 mg BID - Final Study Period0/21 (0%)0/21 (0%)2/21 (9.5%)
GSK2330672 90 mg BID - Final Study Period0/17 (0%)0/17 (0%)2/17 (11.8%)
Placebo - Follow-up0/35 (0%)0/35 (0%)0/35 (0%)
GSK2330672 20 mg QD - Follow-up0/16 (0%)1/16 (6.3%)0/16 (0%)
GSK2330672 90 mg QD - Follow-up0/23 (0%)0/23 (0%)0/23 (0%)
GSK2330672 180 mg QD - Follow-up0/27 (0%)1/27 (3.7%)0/27 (0%)
GSK2330672 40 mg BID - Follow-up0/22 (0%)0/22 (0%)0/22 (0%)
GSK2330672 90 mg BID - Follow-up0/22 (0%)0/22 (0%)0/22 (0%)
Most frequent serious events
Most frequent serious events
EventPlacebo - Main Study PeriodGSK2330672 20 mg QD - Main Study PeriodGSK2330672 90 mg QD - Main Study PeriodGSK2330672 180 mg QD - Main Study PeriodGSK2330672 40 mg BID - Main Study PeriodGSK2330672 90 mg BID - Main Study PeriodPlacebo - Final Study PeriodGSK2330672 20 mg QD - Final Study PeriodGSK2330672 90 mg QD - Final Study PeriodGSK2330672 180 mg QD - Final Study PeriodGSK2330672 40 mg BID - Final Study PeriodGSK2330672 90 mg BID - Final Study PeriodPlacebo - Follow-upGSK2330672 20 mg QD - Follow-upGSK2330672 90 mg QD - Follow-upGSK2330672 180 mg QD - Follow-upGSK2330672 40 mg BID - Follow-upGSK2330672 90 mg BID - Follow-up
Lower respiratory tract infectionInfections and infestations0/360/160/230/270/230/220/350/160/190/190/210/170/351/160/230/270/220/22
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/360/161/230/270/230/220/350/160/190/190/210/170/350/160/230/270/220/22
ConstipationGastrointestinal disorders0/360/160/230/270/230/220/350/160/190/190/210/170/350/160/231/270/220/22
Most frequent other events
Showing 10 of 57
Most frequent other events
EventPlacebo - Main Study PeriodGSK2330672 20 mg QD - Main Study PeriodGSK2330672 90 mg QD - Main Study PeriodGSK2330672 180 mg QD - Main Study PeriodGSK2330672 40 mg BID - Main Study PeriodGSK2330672 90 mg BID - Main Study PeriodPlacebo - Final Study PeriodGSK2330672 20 mg QD - Final Study PeriodGSK2330672 90 mg QD - Final Study PeriodGSK2330672 180 mg QD - Final Study PeriodGSK2330672 40 mg BID - Final Study PeriodGSK2330672 90 mg BID - Final Study PeriodPlacebo - Follow-upGSK2330672 20 mg QD - Follow-upGSK2330672 90 mg QD - Follow-upGSK2330672 180 mg QD - Follow-upGSK2330672 40 mg BID - Follow-upGSK2330672 90 mg BID - Follow-up
DiarrhoeaGastrointestinal disorders4/366/1615/2318/2712/2315/221/351/160/190/191/210/170/350/160/230/270/220/22
Abdominal painGastrointestinal disorders3/363/164/238/272/234/220/351/160/190/190/210/170/350/160/230/270/220/22
ConstipationGastrointestinal disorders0/360/164/230/270/230/220/350/161/190/190/210/170/350/160/230/270/220/22
NauseaGastrointestinal disorders1/361/161/234/270/232/221/351/160/190/190/210/170/350/160/230/270/220/22
NasopharyngitisInfections and infestations1/361/161/231/270/233/220/350/160/190/190/210/170/350/160/230/270/220/22
HeadacheNervous system disorders0/361/163/232/271/231/220/350/161/190/190/210/170/350/160/230/270/220/22
Abdominal pain upperGastrointestinal disorders0/362/160/232/271/230/220/350/160/190/190/210/170/350/160/230/270/220/22
AstheniaGeneral disorders0/362/160/231/271/230/220/350/160/190/190/210/170/350/160/230/270/220/22
Dry eyeEye disorders0/362/161/230/270/230/220/350/160/190/190/210/170/350/160/230/270/220/22
Dry mouthGastrointestinal disorders0/362/161/230/271/230/220/350/160/190/190/210/170/350/160/230/270/220/22

Baseline characteristics

Baseline characteristics is presented for Safety Population which consisted of all randomized participants who took at least one dose of randomized study treatment.

Age, Continuous
Age, Continuous(Years)PlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BIDTotal
Mean54.4 ± 11.0658.5 ± 7.3552.5 ± 12.3258.9 ± 11.1055.6 ± 11.2356.2 ± 11.3255.8 ± 11.04
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BIDTotal
Female341621252220138
Male2022129
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboGSK2330672 20 mg QDGSK2330672 90 mg QDGSK2330672 180 mg QDGSK2330672 40 mg BIDGSK2330672 90 mg BIDTotal
American Indian or Alaskan Native0000101
Asian - Japanese Heritage86674738
White - White/Caucasian/European Heritage261017191615103
Multiple0001001
Unknown2000204
08

Study locations

66 sites
  • GSK Investigational Site
    Phoenix, Arizona 85054, United States
  • GSK Investigational Site
    Sacramento, California 95817, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Novi, Michigan 48377, United States
  • GSK Investigational Site
    Manhasset, New Jersey 11030, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    Allentown, Pennsylvania 18104, United States
  • GSK Investigational Site
    Dallas, Texas 75390-8887, United States
  • GSK Investigational Site
    Seattle, Washington 981104, United States
  • GSK Investigational Site
    Camperdown, New South Wales 2050, Australia
  • GSK Investigational Site
    Herston, Queensland 4029, Australia
  • GSK Investigational Site
    Prahran, Victoria 3181, Australia
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    Calgary, Alberta T2N 4Z6, Canada
  • GSK Investigational Site
    Edmonton, Alberta T6G 2C8, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R3E 3P4, Canada
  • GSK Investigational Site
    London, Ontario N6A 5A5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2C4, Canada
  • GSK Investigational Site
    Montréal, Quebec H2X 0A9, Canada
  • GSK Investigational Site
    Clermont-Ferrand, 63003, France
  • GSK Investigational Site
    Grenoble Cedex 9, 38043, France
  • GSK Investigational Site
    Lille cedex, 59037, France
  • GSK Investigational Site
    Paris cedex 12, 75571, France
  • GSK Investigational Site
    Pessac cedex, 33604, France
  • GSK Investigational Site
    Erlangen, Bayern 91054, Germany
  • GSK Investigational Site
    Homburg, Saarland 66421, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Bologna, Emilia-Romagna 40138, Italy
  • GSK Investigational Site
    Milano, Lombardia 20142, Italy
  • GSK Investigational Site
    Monza (MB), Lombardia 20900, Italy
  • GSK Investigational Site
    Firenze, Toscana 50134, Italy
  • GSK Investigational Site
    Padova, Veneto 35128, Italy
  • GSK Investigational Site
    Chiba, 270-1694, Japan
  • GSK Investigational Site
    Fukui, 918-8503, Japan
  • GSK Investigational Site
    Gunma, 371-8511, Japan
  • GSK Investigational Site
    Hiroshima, 730-8619, Japan
  • GSK Investigational Site
    Hokkaido, 006-8555, Japan
  • GSK Investigational Site
    Kagawa, 760-8557, Japan
  • GSK Investigational Site
    Kanagawa, 252-0375, Japan
  • GSK Investigational Site
    Nagasaki, 856-8562, Japan
  • GSK Investigational Site
    Osaka, 545-8586, Japan
  • GSK Investigational Site
    Osaka, 591-8025, Japan
  • GSK Investigational Site
    Tokyo, 105-8471, Japan
  • GSK Investigational Site
    Tokyo, 173-8606, Japan
  • GSK Investigational Site
    Tokyo, 181-8611, Japan
  • GSK Investigational Site
    Czestochowa, 42-217, Poland
  • GSK Investigational Site
    Katowice, 40-506, Poland
  • GSK Investigational Site
    Myslowice, 41-400, Poland
  • GSK Investigational Site
    Warszawa, 00-332, Poland
  • GSK Investigational Site
    Wroclaw, 50-349, Poland
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Madrid, 28007, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Sevilla, 41013, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain
  • GSK Investigational Site
    Basingstoke, RG24 9NA, United Kingdom
  • GSK Investigational Site
    Edgbaston, B15 2GW, United Kingdom
  • GSK Investigational Site
    Glasgow, G31 2ER, United Kingdom
  • GSK Investigational Site
    Liverpool., L7 8XP, United Kingdom
  • GSK Investigational Site
    London, NW3 2QG, United Kingdom
  • GSK Investigational Site
    Manchester, M13 9WU, United Kingdom
  • GSK Investigational Site
    Middlesbrough, TS4 3BW, United Kingdom
  • GSK Investigational Site
    Newcastle-upon-Tyne, NE1 4LP, United Kingdom
  • GSK Investigational Site
    Nottingham, NG7 2UH, United Kingdom
  • GSK Investigational Site
    Plymouth, PL6 8DH, United Kingdom
  • GSK Investigational Site
    Sheffield, S5 7AU, United Kingdom
09

References and documents

Publications

  • Levy C, Kendrick S, Bowlus CL, Tanaka A, Jones D, Kremer AE, Mayo MJ, Haque N, von Maltzahn R, Allinder M, Swift B, McLaughlin MM, Hirschfield GM; GLIMMER Study Group. GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus. Clin Gastroenterol Hepatol. 2023 Jul;21(7):1902-1912.e13. doi: 10.1016/j.cgh.2022.10.032. Epub 2022 Nov 4. PubMed 36343847 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Apr 2020, 39 months.

Results were first posted in May 2021, 1 year after primary completion.

Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2016
First posted
Nov 17, 2016
StartActual
Jan 11, 2017
Primary completionActual
Apr 15, 2020
CompletionActual
Apr 15, 2020
Results first posted
May 4, 2021
Last update
May 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02966834
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 17, 2016
Start date
Jan 11, 2017
Primary completion
Apr 15, 2020
Completion
Apr 15, 2020
Results posted
May 4, 2021
Last update
May 4, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linerixibat

Start the discussion